Allogene Therapeutics Reports Fourth-Quarter Earnings and Revenue Beat
Allogene Therapeutics reported fourth-quarter results that surpassed Wall Street estimates for both earnings and revenue.
Allogene Therapeutics posted fourth-quarter financial results that outperformed consensus analyst expectations. The company reported an earnings per share figure that beat estimates by $0.04, alongside revenue that came in above projections.
Financial details regarding the exact net income figures, operating expenses, and specific revenue totals were not detailed in the preliminary release, but the performance marks a positive surprise relative to Wall Street forecasts.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →